Comparison of two drugs for luteal phase support in IVF cycles
Not Applicable
Completed
- Conditions
- Health Condition 1: N979- Female infertility, unspecified
- Registration Number
- CTRI/2020/02/023552
- Lead Sponsor
- All India Institute of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 69
Inclusion Criteria
1. FSH less than and equal to 12 IU/L
2. AMH more than and equal to 1.5 ng/ml
3. BMI 18 to 30 Kg/ m2
4. E2 more than 2500 pg/ml on the day of ovulation trigger
Exclusion Criteria
1. More than and equal to 2 Previous IVF failures
2. Endometriosis
3. Hydrosalpinges (unilateral/bilateral)
4. Uterine factor unfavorable for implantation (adenomyosis, intrauterine adhesions, thin
endometrium, fibroids)
5. More than 20 oocytes retrieved
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method clinical pregnancy rate <br/ ><br>Timepoint: To compare GnRH agonist with low dose hCG for luteal phase support among GnRH <br/ ><br>agonist triggered antagonist cycles in terms of clinical pregnancy rate <br/ ><br>
- Secondary Outcome Measures
Name Time Method 1. Hormonal dynamics (E2,P4,LH) after oocyte retrieval <br/ ><br>2. Implantation Rate <br/ ><br>3. Ongoing pregnancy rate <br/ ><br>4.OHSS rate <br/ ><br>5.Miscarriage rate <br/ ><br>Timepoint: 2 years